SGMO Earnings Prediction
The chart below shows how SGMO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SGMO sees a +3.99% change in stock price 10 days leading up to the earnings, and a -7.89% change 10 days following the report. On the earnings day itself, the stock moves by +0.34%. This data can give you a slight idea of what to expect for the next quarter's release.
SGMO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
49.41M
425.77%
13779.78%
Gross Margin
--
--
--
Operating Margin
21.52%
103.28%
-100.21%
Net Margin
21.60%
101.95%
-100.21%
EPS
0.04
106.78%
-122.22%
No Data Available
SGMO Earnings Analysis
Sangamo Therapeutics, Inc. Common Stock Corporation (SGMO.O) Earnings Conference Call
Positive
Regulatory Advancement in Fabry Program: Sangamo has transformed from a Phase I/II company to a pre-BLA company as a result of significant regulatory developments in our Fabry disease program.
Hemophilia A Program Discussions: Pfizer continues to engage in discussions with regulatory authorities concerning our hemophilia A program, both of which have the potential to provide a long-term financial foundation for our core neurology pipeline.
Neurology License Agreement: We signed a neurology epigenetic regulation and capsid delivery license agreement with Genentech and received $50 million in upfront license fees and milestone payments.
First IND Application Submitted: We submitted our first ever IND application for a neurology indication, demonstrating that Sangamo is steadily executing upon our strategy, driving potential medicines towards patients in need.
Exclusive License for Tau Repressors: We have granted Genentech an exclusive license to our highly potent zinc finger repressors that are directed to tau, a critical gene involved in Alzheimer's disease and other tauopathies.
Negative
Cash Runway Stability: Sangamo's cash runway remains unchanged and is sufficient to fund planned operations into the first quarter of 2025, absent any potential funding from a Fabry partnership.
Clinical Trial Uncertainties: The anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions and regulatory approvals are subject to certain risks and uncertainties.
Collaboration Revenue Uncertainty: Sangamo's ability to earn and receive payments from its collaboration and license agreements, including the Genentech and Pfizer agreements, is uncertain and may not materialize as expected.
Regulatory Progress Impact: The company has not provided specific details on the statistical analysis that the agency has asked them to do, which may impact their regulatory progress.
Fabry Disease Treatment Progress: Sangamo's clinical research has shown that the treatment for Fabry disease is still in the early stages and may not meet the expected outcomes for patients.
SGMO FAQs
How does SGMO typically perform around its earnings report dates?
Is Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SGMO Earning Call Sentiment
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SGMO.O
-2.24%Positive
The earnings call summary reveals a positive sentiment due to the Genentech partnership and potential milestone payments from Pfizer, which extend the cash runway and provide financial stability. Despite regulatory and funding risks, the collaboration with a major player like Genentech and potential for significant milestone payments are strong positives. The Q&A section reveals some uncertainties, but the overall sentiment remains positive, with strong earnings and optimistic guidance likely boosting the stock price in the short term.
